Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 105
- Registration Number
- NCT03638778
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 215
- Registration Number
- NCT03631186
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (NNC0113-2023)
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT03617081
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Semaglutide, 0.25 mgDrug: Semaglutide, 0.5 mgDrug: Semaglutide, 1.0 mgDevice: DV3372Device: PDS290 pen-injector
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT03611322
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
Phase 3
Completed
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 611
- Registration Number
- NCT03611582
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Olympia, Washington, United States
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
Phase 1
Completed
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 96
- Registration Number
- NCT03600480
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Semaglutide, 1.0 mg/mLDrug: Semaglutide, 0.5 mg/mLDrug: Semaglutide, 1.34 mg/mLDrug: Semaglutide, 2.0 mg/mLDevice: DV3372, 0.5 mg/mLDevice: DV3372, 1.0 mg/mLDevice: PDS290Device: NovoPen®4
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 68
- Registration Number
- NCT03598621
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Standard of care
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1278
- Registration Number
- NCT03596450
- Locations
- 🇺🇸
Primary Care Research, Atlanta, Georgia, United States
🇺🇸Palm Research Center Inc-Vegas, Las Vegas, Nevada, United States
🇺🇸SC Clinical Research, Inc., Garden Grove, California, United States
Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1
- Registration Number
- NCT03588741
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Awareness, Care & Treatment In Obesity Management - An International Observation
Completed
- Conditions
- Obesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 17287
- Registration Number
- NCT03584191
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Gatwick, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath